A review of synthetic strategy, SAR, docking, simulation studies, and mechanism of action of isoxazole derivatives as anticancer agents

References

• Abotaleb, M., Kubatka, P., Caprnda, M., Varghese, E., Zolakova, B., Zubor, P., Opatrilova, R., Kruzliak, P., Stefanicka, P., & Büsselberg, D. (2018). Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. Biomedicine & Pharmacotherapy, 101, 458–477. https://doi.org/10.1016/j.biopha.2018.02.108
   PubMed Web of Science ®Google Scholar
• Acar Çevik, U., Celik, I., Işık, A., Ahmad, I., Patel, H., Özkay, Y., & Kaplancıklı, Z. A. (2022). Design, synthesis, molecular modeling, DFT, ADME and biological evaluation studies of some new 1,3,4-oxadiazole linked benzimidazoles as anticancer agents and aromatase inhibitors. Journal of Biomolecular Structure and Dynamics, 41(5), 1–15. https://doi.org/10.1080/07391102.2022.2025906
   Web of Science ®Google Scholar
• Ageed, A. S. M. A. (2019). Electrocardiogram changes in cancer patients treated with 5-fluorouracil chemotherapy at National Cancer Institute-University of Gezira, Sudan (2018). University of Gezira.
   Google Scholar
• Alam, F., Rahman, S. U., Ullah, S., & Gulati, K. (2018). Medical image registration in image guided surgery: Issues, challenges and research opportunities. Biocybernetics and Biomedical Engineering, 38(1), 71–89. https://doi.org/10.1016/j.bbe.2017.10.001
   Web of Science ®Google Scholar
• Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast, 66, 15–23. https://doi.org/10.1016/j.breast.2022.08.010
   PubMed Web of Science ®Google Scholar
• Arya, G. C., Kaur, K., & Jaitak, V. (2021). Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies. European Journal of Medicinal Chemistry, 221, 113511. https://doi.org/10.1016/j.ejmech.2021.113511
   PubMed Web of Science ®Google Scholar
• Bai, R., Schwartz, R. E., Kepler, J. A., Pettit, G. R., & Hamel, E. (1996). Characterization of the interaction of cryptophycin 1 with tubulin: Binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction. Cancer Research, 56(19), 4398–4406.
   PubMed Web of Science ®Google Scholar
• Ban, Y., Wang, Y., Liu, S., Yang, B., Liu, M., Yin, L., & Zheng, W. (2022). 2D/3D multimode medical image alignment based on spatial histograms. Applied Sciences, 12(16), 8261. https://doi.org/10.3390/app12168261
   Google Scholar
• Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., Clark, E., Benyunes, M. C., Ross, G., & Swain, S. M., CLEOPATRA Study Group. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine, 366(2), 109–119. https://doi.org/10.1056/NEJMoa1113216
   PubMed Web of Science ®Google Scholar
• Bates, D., & Eastman, A. (2017). Microtubule destabilising agents: Far more than just antimitotic anticancer drugs. British Journal of Clinical Pharmacology, 83(2), 255–268. https://doi.org/10.1111/bcp.13126
   PubMed Web of Science ®Google Scholar
• Boszkiewicz, K., Piwowar, A., & Petryszyn, P. (2022). Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients—A systematic review and meta-analysis. Journal of Clinical Medicine, 11(11), 3133. https://doi.org/10.3390/jcm11113133
   PubMed Web of Science ®Google Scholar
• Bradley, R., Braybrooke, J., Gray, R., Hills, R. K., Liu, Z., Pan, H., Peto, R., Dodwell, D., McGale, P., Taylor, C., Francis, P. A., Gnant, M., Perrone, F., Regan, M. M., Berry, R., Boddington, C., Clarke, M., Davies, C., Davies, L., … Swain, S. M. (2022). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology, 23(3), 382–392. https://doi.org/10.1016/S1470-2045(21)00758-0
   PubMed Web of Science ®Google Scholar
• Caciolla, J., Bisi, A., Belluti, F., Rampa, A., & Gobbi, S. (2020). Reconsidering aromatase for breast cancer treatment: New roles for an old target. Molecules, 25(22), 5351. https://doi.org/10.3390/molecules25225351
   PubMed Web of Science ®Google Scholar
• Chatterjee, G., Mukherjee, S., & Majumder, D. (2016). Efficacy and toxicity assessment of different clinically used small molecular tyrosine kinase inhibitors by computational molecular docking method. Journal of Metabolomics and Systems Biology, 2(1), 9.
   Google Scholar
• Cleary, K., & Peters, T. M. (2010). Image-guided interventions: Technology review and clinical applications. Annual Review of Biomedical Engineering, 12, 119–142. https://doi.org/10.1146/annurev-bioeng-070909-105249
   PubMed Web of Science ®Google Scholar
• Dandriyal, J., Singla, R., Kumar, M., & Jaitak, V. (2016). Recent developments of C-4 substituted coumarin derivatives as anticancer agents. European Journal of Medicinal Chemistry, 119, 141–168. https://doi.org/10.1016/j.ejmech.2016.03.087
   PubMed Web of Science ®Google Scholar
• Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., Gödtel-Armbrust, U., & Wojnowski, L. (2014). Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer, 14(1), 11. https://doi.org/10.1186/1471-2407-14-842
   PubMedGoogle Scholar
• DeSantis, C., Siegel, R., Bandi, P., & Jemal, A. (2011). Breast cancer statistics, 2011. CA: A Cancer Journal for Clinicians, 61(6), 408–418. https://doi.org/10.3322/caac.20134
   Web of Science ®Google Scholar
• Dinesh, V. C., Hareeshbabu, E., & Krishnakumar, K. (2019). Synthesis of hybrid molecules of isoxazole derivatives in search of new anticancer drugs—A review. International Journal of Advance Research, Ideas and Innovations in Technology, 5(3), 8.
   Google Scholar
• Drappatz, J., Norden, A. D., Wong, E. T., Doherty, L. M., Lafrankie, D. C., Ciampa, A., Kesari, S., Sceppa, C., Gerard, M., Phan, P., Schiff, D., Batchelor, T. T., Ligon, K. L., Young, G., Muzikansky, A., Weiss, S. E., & Wen, P. Y. (2010). Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics, 78(1), 85–90. https://doi.org/10.1016/j.ijrobp.2009.07.1741
   PubMed Web of Science ®Google Scholar
• Duan, C., Deng, H., Xiao, S., Xie, J., Li, H., Zhao, X., Han, D., Sun, X., Lou, X., Ye, C., & Zhou, X. (2022). Accelerate gas diffusion-weighted MRI for lung morphometry with deep learning. European Radiology, 32(1), 702–713. https://doi.org/10.1007/s00330-021-08126-y
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. The Lancet, 386(10001), 1341–1352.
   PubMed Web of Science ®Google Scholar
• Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicologic Pathology, 35(4), 495–516. https://doi.org/10.1080/01926230701320337
   PubMed Web of Science ®Google Scholar
• El-Sawy, E. R., Mandour, A. H., El-Hallouty, S. M., Shaker, K. H., & Abo-Salem, H. M. (2013). Synthesis, antimicrobial and anticancer activities of some new N-methylsulphonyl and N-benzenesulphonyl-3-indolyl heterocycles: 1st Cancer Update. Arabian Journal of Chemistry, 6(1), 67–78. https://doi.org/10.1016/j.arabjc.2012.04.003
   Web of Science ®Google Scholar
• Ercisli, M. F., Kahrizi, D., & Aziziaram, Z. (2021). Environmental factors affecting the risk of breast cancer and the modulating role of vitamin D on this malignancy. Central Asian Journal of Environmental Science and Technology Innovation, 2(4), 175–183.
   Google Scholar
• Ertel, A., Dean, J. L., Rui, H., Liu, C., Witkiewicz, A., Knudsen, K. E., & Knudsen, E. S. (2010). RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle, 9(20), 4153–4163. https://doi.org/10.4161/cc.9.20.13454
   PubMed Web of Science ®Google Scholar
• Forrest, A. P., Stewart, H. J., Everington, D., Prescott, R. J., McArdle, C. S., Harnett, A. N., Smith, D. C., & George, W. D. (1996). Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. The Lancet, 348(9029), 708–713. https://doi.org/10.1016/s0140-6736(96)02133-2
   PubMed Web of Science ®Google Scholar
• Gasparini, G. (2000). Prognostic value of vascular endothelial growth factor in breast cancer. The Oncologist, 5(S1), 37–44. https://doi.org/10.1634/theoncologist.5-2004-37
   PubMedGoogle Scholar
• Goldenberg, M. M. (2013). Pharmaceutical approval update. Pharmacy and Therapeutics, 38(5), 246.
   Google Scholar
• Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., Winquist, E., Sarto, G. E., Garber, J. E., Fabian, C. J., Pujol, P., Maunsell, E., Farmer, P., Gelmon, K. A., Tu, D., & Richardson, H., NCIC CTG MAP.3 Study Investigators. (2011). Exemestane for breast-cancer prevention in postmenopausal women. The New England Journal of Medicine, 364(25), 2381–2391. https://doi.org/10.1056/NEJMoa1103507
   PubMed Web of Science ®Google Scholar
• Gujjarappa, R., Sravani, S., Kabi, A. K., Garg, A., Vodnala, N., Tyagi, U., Kaldhi, D., Singh, V., Gupta, S., & Malakar, C. C. (2022). An overview on biological activities of oxazole, isoxazoles and 1,2,4-oxadiazoles derivatives. In B. P. Swain (Ed.), Nanostructured biomaterials. Materials horizons: From nature to nanomaterials (pp. 379–400). Springer. https://doi.org/10.1007/978-981-16-8399-2_10
   Google Scholar
• Harismah, K., Fazeli, F., Amini, I., Da’i, M., & Mirzaei, M. (2022). In silico effects of steviol on depression, inflammation and cancer biomarkers. Biointerface Research in Applied Chemistry, 12, 8385–8393. https://doi.org/10.33263/BRIAC126.83858393
   Web of Science ®Google Scholar
• Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014). Apoptosis and molecular targeting therapy in cancer. BioMed Research International, 2014, 1–23. https://doi.org/10.1155/2014/150845
   Web of Science ®Google Scholar
• Hosseini, A., & Ghorbani, A. (2015). Cancer therapy with phytochemicals: Evidence from clinical studies. Avicenna Journal of Phytomedicine, 5(2), 84. https://pubmed.ncbi.nlm.nih.gov/25949949
   PubMed Web of Science ®Google Scholar
• Hu, C., Hart, S. N., Gnanaolivu, R., Huang, H., Lee, K. Y., Na, J., Gao, C., Lilyquist, J., Yadav, S., Boddicker, N. J., Samara, R., Klebba, J., Ambrosone, C. B., Anton-Culver, H., Auer, P., Bandera, E. V., Bernstein, L., Bertrand, K. A., Burnside, E. S., … Couch, F. J. (2021). A population-based study of genes previously implicated in breast cancer. The New England Journal of Medicine, 384(5), 440–451. https://doi.org/10.1056/NEJMoa2005936
   PubMed Web of Science ®Google Scholar
• Hu, M.-J., Zhang, B., Yang, H.-K., Liu, Y., Chen, Y.-R., Ma, T.-Z., Lu, L., You, W.-W., & Zhao, P.-L. (2015). Design, synthesis and molecular docking studies of novel indole–pyrimidine hybrids as tubulin polymerization inhibitors. Chemical Biology & Drug Design, 86(6), 1491–1500. https://doi.org/10.1111/cbdd.12616
   PubMed Web of Science ®Google Scholar
• Hu, Z., Zhao, T. V., Huang, T., Ohtsuki, S., Jin, K., Goronzy, I. N., Wu, B., Abdel, M. P., Bettencourt, J. W., Berry, G. J., Goronzy, J. J., & Weyand, C. M. (2022). The transcription factor RFX5 coordinates antigen-presenting function and resistance to nutrient stress in synovial macrophages. Nature Metabolism, 4(6), 759–774. https://doi.org/10.1038/s42255-022-00585-x
   PubMedGoogle Scholar
• Iacoviello, L., Bonaccio, M., de Gaetano, G., & Donati, M. B. (2021). Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis. Seminars in Cancer Biology, 72, 4–10. https://doi.org/10.1016/j.semcancer.2020.02.010
   PubMed Web of Science ®Google Scholar
• Islami, F., Liu, Y., Jemal, A., Zhou, J., Weiderpass, E., Colditz, G., Boffetta, P., & Weiss, M. (2015). Breastfeeding and breast cancer risk by receptor status—A systematic review and meta-analysis. Annals of Oncology, 26(12), 2398–2407. https://doi.org/10.1093/annonc/mdv379
   PubMed Web of Science ®Google Scholar
• Jiao, Q., Bi, L., Ren, Y., Song, S., Wang, Q., & Wang, Y-s (2018). Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Molecular Cancer, 17(1), 1–12. https://doi.org/10.1186/s12943-018-0801-5
   PubMedGoogle Scholar
• Kaur, R., Kaur, G., Gill, R. K., Soni, R., & Bariwal, J. (2014). Recent developments in tubulin polymerization inhibitors: An overview. European Journal of Medicinal Chemistry, 87, 89–124. https://doi.org/10.1016/j.ejmech.2014.09.051
   PubMed Web of Science ®Google Scholar
• Kavitha, R., Jothi, D. K., Saravanan, K., Swain, M. P., Gonzáles, J. L. A., Bhardwaj, R. J., & Adomako, E. (2023). Ant colony optimization-enabled CNN deep learning technique for accurate detection of cervical cancer. BioMed Research International, 2023, 1742891. https://doi.org/10.1155/2023/1742891
   PubMed Web of Science ®Google Scholar
• Kelsey, J. L., Gammon, M. D., & John, E. M. (1993). Reproductive factors and breast cancer. Epidemiologic Reviews, 15(1), 36–47. https://doi.org/10.1093/oxfordjournals.epirev.a036115
   PubMed Web of Science ®Google Scholar
• Khalifa, M. M., Al-Karmalawy, A. A., Elkaeed, E. B., Nafie, M. S., Tantawy, M. A., Eissa, I. H., & Mahdy, H. A. (2022). Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: Design, synthesis, anti-proliferative, docking, and in vivo studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 299–314. https://doi.org/10.1080/14756366.2021.2007905
   PubMed Web of Science ®Google Scholar
• Kim, K. H., Moon, E., Choi, S. U., Kim, S. Y., & Lee, K. R. (2013). Polyphenols from the bark of Rhus verniciflua and their biological evaluation on antitumor and anti-inflammatory activities. Phytochemistry, 92, 113–121. https://doi.org/10.1016/j.phytochem.2013.05.005
   PubMed Web of Science ®Google Scholar
• Koukourakis, M. I., Manavis, J., Simopoulos, C., Liberis, V., Giatromanolaki, A., & Sivridis, E. (2005). Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer. American Journal of Clinical Oncology, 28(5), 495–500. https://doi.org/10.1097/01.coc.0000182440.11653.5f
   PubMed Web of Science ®Google Scholar
• Krikorian, S. A., & Shamim, K. (2013). Adherence issues for oral antineoplastics: A focus on prevention and management of side effects related to targeted therapies. American Journal of Lifestyle Medicine, 7(3), 206–222. https://doi.org/10.1177/1559827612466996
   Google Scholar
• Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., Hengartner, M., Knight, R. A., Kumar, S., Lipton, S. A., Malorni, W., Nuñez, G., Peter, M. E., Tschopp, J., Yuan, J., … Melino, G, Nomenclature Committee on Cell Death 2009. (2009). Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death and Differentiation, 16(1), 3–11. https://doi.org/10.1038/cdd.2008.150
   PubMed Web of Science ®Google Scholar
• Lan, J.-S., Liu, L., Zeng, R.-F., Qin, Y.-H., Hou, J.-W., Xie, S.-S., Yue, S., Yang, J., Ho, R. J., Ding, Y., & Zhang, T. (2021). Tumor-specific carrier-free nanodrugs with GSH depletion and enhanced ROS generation for endogenous synergistic anti-tumor by a chemotherapy-photodynamic therapy. Chemical Engineering Journal, 407, 127212. https://doi.org/10.1016/j.cej.2020.127212
   Web of Science ®Google Scholar
• Lee, Y. J., Shin, K. J., Jang, H.-J., Noh, D.-Y., Ryu, S. H., & Suh, P.-G. (2021). Phospholipase signaling in breast cancer. Translational Research in Breast Cancer, 1187, 23–52. https://doi.org/10.1007/978-981-32-9620-6_2
   Google Scholar
• Liu, H., Liu, M., Li, D., Zheng, W., Yin, L., & Wang, R. (2022). Recent advances in pulse-coupled neural networks with applications in image processing. Electronics, 11(20), 3264. https://doi.org/10.3390/electronics11203264
   Web of Science ®Google Scholar
• Li, B., Wang, W., Zhao, L., Yan, D., Li, X., Gao, Q., Zheng, J., Zhou, S., Lai, S., Feng, Y., Zhang, J., Jiang, H., Long, C., Gan, W., Chen, X., Wang, D., Tang, B. Z., & Liao, Y. (2023). Multifunctional AIE nanosphere-based “nanobomb” for trimodal imaging-guided photothermal/photodynamic/pharmacological therapy of drug-resistant bacterial infections. ACS Nano, 17(5), 4601–4618. https://doi.org/10.1021/acsnano.2c10694
   PubMed Web of Science ®Google Scholar
• Li, S., Zhao, Y., He, X., Kim, T.-H., Kuharsky, D. K., Rabinowich, H., Chen, J., Du, C., & Yin, X.-M. (2002). Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. The Journal of Biological Chemistry, 277(30), 26912–26920. https://doi.org/10.1074/jbc.M200726200
   PubMed Web of Science ®Google Scholar
• Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-Fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews. Cancer, 3(5), 330–338. https://doi.org/10.1038/nrc1074
   PubMed Web of Science ®Google Scholar
• Lorenz, K., Lohse, M. J., & Quitterer, U. (2003). Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature, 426(6966), 574–579. https://doi.org/10.1038/nature02158
   PubMed Web of Science ®Google Scholar
• Lowe, S. W., & Lin, A. W. (2000). Apoptosis in cancer. Carcinogenesis, 21(3), 485–495. https://doi.org/10.1093/carcin/21.3.485
   PubMed Web of Science ®Google Scholar
• Lu, Y., Chen, J., Xiao, M., Li, W., & Miller, D. D. (2012). An overview of tubulin inhibitors that interact with the colchicine binding site. Pharmaceutical Research, 29(11), 2943–2971. https://doi.org/10.1007/s11095-012-0828-z
   PubMed Web of Science ®Google Scholar
• Martinvalet, D., Zhu, P., & Lieberman, J. (2005). Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity, 22(3), 355–370. https://doi.org/10.1016/j.immuni.2005.02.004
   PubMed Web of Science ®Google Scholar
• McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008). Taxanes, microtubules and chemoresistant breast cancer. Biochimica et Biophysica Acta, 1785(2), 96–132. https://doi.org/10.1016/j.bbcan.2007.10.004
   PubMed Web of Science ®Google Scholar
• Miller, K. D., & Camp, M. (2021). The breast cancer book: A trusted guide for you and your loved ones. JHU Press.
   Google Scholar
• Mirzaei, M., & Nazemi, H. (2022). In silico interactions between curcumin derivatives and monoamine oxidase-A enzyme. Biointerface Research in Applied Chemistry, 12, 3752–3761. https://doi.org/10.33263/BRIAC123.37523761
   Web of Science ®Google Scholar
• Nassar, E. (2010). Synthesis,(in vitro) antitumor and antimicrobial activity of some pyrazoline, pyridine, and pyrimidine derivatives linked to indole moiety. Journal of American Science, 6(8), 463–471.
   Google Scholar
• Osborne, C. K. (1998). Tamoxifen in the treatment of breast cancer. The New England Journal of Medicine, 339(22), 1609–1618. https://doi.org/10.1056/NEJM199811263392207
   PubMed Web of Science ®Google Scholar
• Panathur, N., Gokhale, N., Dalimba, U., Koushik, P. V., Yogeeswari, P., & Sriram, D. (2015). New indole–isoxazolone derivatives: Synthesis, characterisation and in vitro SIRT1 inhibition studies. Bioorganic & Medicinal Chemistry Letters, 25(14), 2768–2772. https://doi.org/10.1016/j.bmcl.2015.05.015
   PubMed Web of Science ®Google Scholar
• Pandhurnekar, C. P., Pandhurnekar, H. C., Mungole, A. J., Butoliya, S. S., & Yadao, B. G. (2023). A review on recent synthetic strategies and biological activities of isoxazole. Journal of Heterocyclic Chemistry, 60(4), 537–565. https://doi.org/10.1002/jhet.4586
   Web of Science ®Google Scholar
• Park, H. G., Kim, J. H., Dancer, A. N., Kothapalli, K. S., & Brenna, J. T. (2021). The aromatase inhibitor letrozole restores FADS2 function in ER+ MCF7 human breast cancer cells. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 171, 102312. https://doi.org/10.1016/j.plefa.2021.102312
   PubMed Web of Science ®Google Scholar
• Pedada, S. R., Yarla, N. S., Tambade, P. J., Dhananjaya, B. L., Bishayee, A., Arunasree, K. M., Philip, G. H., Dharmapuri, G., Aliev, G., Putta, S., & Rangaiah, G. (2016). Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents. European Journal of Medicinal Chemistry, 112, 289–297. https://doi.org/10.1016/j.ejmech.2016.02.025
   PubMed Web of Science ®Google Scholar
• Perez, E. A. (2009). Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Molecular Cancer Therapeutics, 8(8), 2086–2095. https://doi.org/10.1158/1535-7163.MCT-09-0366
   PubMed Web of Science ®Google Scholar
• Pinkerton, J. V. (2021). Selective estrogen receptor modulators in gynecology practice. Clinical Obstetrics and Gynecology, 64(4), 803–812. https://doi.org/10.1097/GRF.0000000000000647
   PubMed Web of Science ®Google Scholar
• Richardson, C. L., & Schulman, G. E. (1981). Intercalation inhibition assay for compounds that interact with DNA or RNA. Google Patents.
   Google Scholar
• Sait, W. A., Al-Amoudi, S. M., Tawatai, D. A., & Abduljabbar, H. S. (2010). The knowledge of breast cancer among young Saudi females. Saudi Medical Journal, 11, 1242–1244.
   Google Scholar
• Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell, 103(2), 211–225. https://doi.org/10.1016/S0092-8674(00)00114-8
   PubMed Web of Science ®Google Scholar
• Scriven, P., Coulson, S., Haines, R., Balasubramanian, S., Cross, S., & Wyld, L. (2009). Activation and clinical significance of the unfolded protein response in breast cancer. British Journal of Cancer, 101(10), 1692–1698. https://doi.org/10.1038/sj.bjc.6605365
   PubMed Web of Science ®Google Scholar
• Selamoglu, Z. (2017a). Biotechnological approaches on anticancer activity of flavonoids-mini review. Modern Approaches to Drug Design, 1(1-1).
   Google Scholar
• Selamoglu, Z. (2017b). Polyphenolic compounds in human health with pharmacological properties. Journal of Traditional Medicine & Clinical Naturopathy, 06(04), 138. https://doi.org/10.4172/2573-4555.1000e138
   Google Scholar
• Selamoglu, Z. (2018). Traditional medicine & clinical naturopathy. Pharmaceutical Research, 16, 92–98. https://doi.org/10.4172/2573-4555.1000e146
   Google Scholar
• Shakibaei, M., Monzavi, H., Rabbani, Z., Bahar Khaleghi Fard, M., Khosroshahi, S. A. T., Mogha-Dam., & M., Goodarzi. (2022). Effect of raloxifene venous thromboembolism. IJCMCR, 22(3), 1. https://doi.org/10.46998/IJCMCR.2022.22.000536
   Google Scholar
• Shoiab, A. A., & Gardouh, A. R. (2020). The nephroprotective effect of Zizphus jujube extract against 5-flurouracil-induced nephropathy. Al-Kitab Journal for Pure Sciences, 4(2), 59–70.
   Google Scholar
• Song, X., Wei, C., & Li, X. (2021). The potential role and status of IL-17 family cytokines in breast cancer. International Immunopharmacology, 95, 107544. https://doi.org/10.1016/j.intimp.2021.107544
   PubMed Web of Science ®Google Scholar
• Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Swift, L. P., Cutts, S. M., Nudelman, A., Levovich, I., Rephaeli, A., & Phillips, D. R. (2008). The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemotherapy and Pharmacology, 61(5), 739–749. https://doi.org/10.1007/s00280-007-0528-2
   PubMed Web of Science ®Google Scholar
• Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998). Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertility and Sterility, 69(4), 709–713. https://doi.org/10.1016/s0015-0282(98)00022-3
   PubMed Web of Science ®Google Scholar
• Tian, Y., Xiao, H., Yang, Y., Zhang, P., Yuan, J., Zhang, W., Chen, L., Fan, Y., Zhang, J., Cheng, H., Deng, T., Yang, L., Wang, W., Chen, G., Wang, P., Gong, P., Niu, X., & Zhang, X. (2023). Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma. Molecular Cancer, 22(1), 5. https://doi.org/10.1186/s12943-022-01706-6
   PubMed Web of Science ®Google Scholar
• Touyz, R. M., Herrmann, S. M., & Herrmann, J. (2018). Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events. Journal of the American Society of Hypertension, 12(6), 409–425. https://doi.org/10.1016/j.jash.2018.03.008
   PubMed Web of Science ®Google Scholar
• Trayes, K. P., & Cokenakes, S. E. (2021). Breast cancer treatment. American Family Physician, 104(2), 171–178.
   PubMed Web of Science ®Google Scholar
• Vecchi, L., Araújo, T. G., Azevedo, F. V. P. D. V., Mota, S. T. S., Ávila, V. D. M. R., Ribeiro, M. A., & Goulart, L. R. (2021). Phospholipase A2 drives tumorigenesis and cancer aggressiveness through its interaction with annexin A1. Cells, 10(6), 1472. https://doi.org/10.3390/cells10061472
   PubMed Web of Science ®Google Scholar
• Wang, L., Yu, Y., Ni, S., Li, D., Liu, J., Xie, D., Chu, H. Y., Ren, Q., Zhong, C., Zhang, N., Li, N., Sun, M., Zhang, Z.-K., Zhuo, Z., Zhang, H., Zhang, S., Li, M., Xia, W., Zhang, Z., … Zhang, G. (2022). Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice. Theranostics, 12(13), 5645–5674. https://doi.org/10.7150/thno.63177
   PubMedGoogle Scholar
• Weber, G. F. (2015). Hormone therapy. In G. F. Weber (Ed.), Molecular therapies of cancer (pp. 303–332). Springer. https://doi.org/10.1007/978-3-319-13278-5_10
   Google Scholar
• Xu, H., Van der Jeught, K., Zhou, Z., Zhang, L., Yu, T., Sun, Y., Li, Y., Wan, C., So, K. M., Liu, D., Frieden, M., Fang, Y., Mosley, A. L., He, X., Zhang, X., Sandusky, G. E., Liu, Y., Meroueh, S. O., Zhang, C., … Lu, X. (2021). Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. Journal of Clinical Investigation, 131(10). https://doi.org/10.1172/JCI146832
   Web of Science ®Google Scholar
• Xu, C., Yang, B., Guo, F., Zheng, W., & Poignet, P. (2020). Sparse-view CBCT reconstruction via weighted Schatten p-norm minimization. Optics Express, 28(24), 35469–35482. https://doi.org/10.1364/OE.404471
   PubMed Web of Science ®Google Scholar
• Yang, B., Liu, C., Zheng, W., Liu, S., & Huang, K. (2018). Reconstructing a 3D heart surface with stereo-endoscope by learning eigen-shapes. Biomedical Optics Express, 9(12), 6222–6236. https://doi.org/10.1364/BOE.9.006222
   PubMed Web of Science ®Google Scholar
• Yu, F., Cai, M., Shao, L., & Zhang, J. (2021). Targeting protein kinases degradation by PROTACs. Frontiers in Chemistry, 9. https://doi.org/10.3389/fchem.2021.679120
   Web of Science ®Google Scholar
• Zanini, S., Renzi, S., Limongi, A. R., Bellavite, P., Giovinazzo, F., & Bermano, G. (2021). A review of lifestyle and environment risk factors for pancreatic cancer. European Journal of Cancer, 145, 53–70. https://doi.org/10.1016/j.ejca.2020.11.040
   PubMed Web of Science ®Google Scholar
• Zeng, Q., Bie, B., Guo, Q., Yuan, Y., Han, Q., Han, X., Chen, M., Zhang, X., Yang, Y., Liu, M., Liu, P., Deng, H., & Zhou, X. (2020). Hyperpolarized Xe NMR signal advancement by metal-organic framework entrapment in aqueous solution. Proceedings of the National Academy of Sciences of the United States of America, 117(30), 17558–17563. https://doi.org/10.1073/pnas.2004121117
   PubMed Web of Science ®Google Scholar
• Zhang, X., Qu, Y.-Y., Liu, L., Qiao, Y.-N., Geng, H.-R., Lin, Y., Xu, W., Cao, J., & Zhao, J.-Y. (2021). Homocysteine inhibits pro-insulin receptor cleavage and causes insulin resistance via protein cysteine-homocysteinylation. Cell Reports, 37(2), 109821. https://doi.org/10.1016/j.celrep.2021.109821
   PubMed Web of Science ®Google Scholar
• Zhao, M., & Ramaswamy, B. (2014). Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World Journal of Clinical Oncology, 5(3), 248. https://doi.org/10.5306/wjco.v5.i3.248
   PubMedGoogle Scholar
• Zheng, L.-S., Wang, F., Li, Y.-H., Zhang, X., Chen, L.-M., Liang, Y.-J., Dai, C.-L., Yan, Y.-Y., Tao, L.-Y., Mi, Y.-J., Yang, A.-K., To, K. K. W., & Fu, L.-W. (2009). Vandetanib (Zactima, ZD6474) antagonizes ABCC1-and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One, 4(4), e5172. https://doi.org/10.1371/journal.pone.0005172
   PubMed Web of Science ®Google Scholar
• Zhou, Y., Zheng, W., & Shen, Z. (2016). A new algorithm for distributed control problem with shortest-distance constraints. Mathematical Problems in Engineering, 2016, 1–6. https://doi.org/10.1155/2016/1604824
   Web of Science ®Google Scholar